Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03760952 · ClinicalTrials.gov registry record
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
A clinical trial of Neoplasms and Refractory Cancer, sponsored by Immatics US.
- Completed
- Registry status
- 242
- Enrollment target
- 4
- Study locations
NCT03760952: Completed study of Neoplasms and Refractory Cancer, sponsored by Immatics US.
NCT03760952 is a study of Neoplasms and Refractory Cancer that has completed, run by Immatics US. The registered enrollment target is 242 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03760952, a study of Neoplasms and Refractory Cancer, has completed, sponsored by Immatics US.
- COMPLETED
- Registry status
- 242 participants
- Enrollment target
- 4
- Study locations
Study Summary
This screening study will identify HLA molecular subtype positive and tumor antigen target(s) positive patients who may be eligible for enrollment into Immatics clinical studies. This screening study is intended for patients with advanced and/or metastatic solid cancers. No treatment intervention will occur as part of this screening study.
Conditions Studied
Study Locations (4)
Illinois
- University of Chicago - Chicago
New York
- Columbia University Medical Center - New York
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Texas
- Oncology Consultants - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2019-02-26 |
| Est. Completion | 2022-11-15 |
What the finished NCT03760952 record still lists
NCT03760952 is an observational study that tracks outcomes without assigning an intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (85% lower).
The record links to 4 conditions, with Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT03760952 reports a single indexed study location in Illinois, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03760952 about?
NCT03760952 is a clinical study titled "Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling". This screening study will identify HLA molecular subtype positive and tumor antigen target(s) positive patients who may be eligible for enrollment into Immatics clinical studies. This screening study is intended for patients with advanced and/or metastatic solid cancers. No treatment intervention wi...
What is the current status of trial NCT03760952?
This trial is currently completed. The enrollment target is 242 participants. The study started on 2019-02-26. Estimated completion is 2022-11-15.
What conditions does trial NCT03760952 study?
This clinical trial studies the following conditions: Neoplasms, Refractory Cancer, Recurrent Cancer, Adult Solid Tumor.
Who is sponsoring clinical trial NCT03760952?
This trial is sponsored by Immatics US, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03760952 being conducted?
This trial has 4 study locations across Illinois, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03760952's enrollment target sits among peer trials
242 40th of 158 higher than 119 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Resilience in East Asian Immigrants for Advance Care Planning Discussions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI